Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia - GlobeNewswire

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia  GlobeNewswire

... ~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial ...



Comments

Popular posts from this blog

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today